The radiosensitising effect of gemcitabine and its main metabolite dFdU under low oxygen conditions is in vitro not dependent on functional HIF-1 protein

Abstract

BackgroundRegions within solid tumours often experience oxygen deprivation, which is associated with resistance to chemotherapy and irradiation. The aim of this study was to evaluate the radiosensitising effect of gemcitabine and its main metabolite dFdU under normoxia versus hypoxia and to determine whether hypoxia-inducible factor 1 (HIF-1) is involved in the radiosensitising mechanism.MethodsStable expression of dominant negative HIF-1α (dnHIF) in MDA-MB-231 breast cancer cells, that ablated endogenous HIF-1 transcriptional activity, was validated by western blot and functionality was assessed by HIF-1α activity assay. Cells were exposed to varying oxygen environments and treated with gemcitabine or dFdU for 24 h, followed by irradiation. Clonogenicity was then assessed. Using radiosensitising conditions, cells were collected for cell cycle analysis.ResultsHIF-1 activity was significantly inhibited in cells stably expressing dnHIF. A clear radiosensitising effect under normoxia and hypoxia was observed for both gemcitabine and dFdU. No significant difference in radiobiological parameters between HIF-1 proficient and HIF-1 deficient MDA-MB-231 cells was demonstrated.ConclusionsFor the first time, radiosensitisation by dFdU, the main metabolite of gemcitabine, was demonstrated under low oxygen conditions. No major role for functional HIF-1 protein in radiosensitisation by gemcitabine or dFdU could be shown.

The hypoxic tumor microenvironment and drug resistance against EGFR inhibitors: preclinical study in cetuximab-sensitive head and neck squamous cell carcinoma cell lines

“…Therefore, we hypothesized that hypoxia might induce anti-EGFR therapeutic resistance. To test this hypothesis, we evaluated the cytotoxicity of the EGFR-blocking monoclonal antibody cetuximab and the small molecule EGFR tyrosine kinase inhibitor erlotinib in three HNSCC cell lines under hypoxic conditions for 24 and 72 h. We previously validated induction of HIF-1α and its downstream targets as well as induction of HIF activity in our experimental model [ 21 ].…”

“…Hypoxic conditions (0% O 2 , 5% CO 2 , 95% N 2 ) were achieved in a Bactron IV anaerobic chamber (Shel Lab, Cornelius, OR, USA) and we used the hypoxia model previously optimized and characterized [ 21 , 22 ]. Measurements with ToxiRae II air oxymeter (Rae BeNeLux, Hoogstraten, Belgium) confirmed that the oxygen tension in the gas phase was stable at <0.1% O 2 .…”

Repurposing FDA approved drugs as radiosensitizers for treating hypoxic prostate cancer

“…In muscle invasive bladder cancer evidence from phase I/II trials supports the concurrent administration of gemcitabine and radiotherapy as a bladder preservation strategy [ 53 , 54 ]. In the breast cancer cell line MDA-MB-231, the SER for gemcitabine and radiation under hypoxia was 1.59 and under normoxia 1.70 [ 55 ]. The radiosensitizing effects of gemcitabine in breast cancer are greater than the effects reported in this study for prostate cancer.…”

Modeling Combined Chemotherapy and Particle Therapy for Locally Advanced Pancreatic Cancer

“…In vitro experiments can provide some information, but do not necessarily reflect the complex in vivo microenvironment. Some chemotherapy drugs used for LAUPC treatment apparently sensitize cell cultures to X-rays ( 17 , 18 ), but simple additive effects are observed when the drugs are given in vitro concomitantly to charged particles ( 19 , 20 ). Moreover, in many clinical protocols, chemotherapy is given as adjuvant or neo-adjuvant, and even when concomitant is often continued after the radiotherapy cycle.…”